Wolwo Pharma(SZ:300357)2022-12-03 09:20Group 1: R&D Progress - The company is conducting clinical trials for "Artemisia annua powder drops" and "Dust mite drops" for atopic dermatitis, currently in Phase III and Phase II respectively [1] - The "Dust mite skin prick diagnostic kit" has received a notice for drug production site inspection, while "Silk protein moisturizing anti-itch dressing" is in preclinical research [2] Group 2: Financial Performance - In Q1 2018, the company achieved revenue of 106.93 million yuan, a year-on-year increase of 31.86% [2] - Net profit attributable to shareholders was 51.95 million yuan, up 35.98% from the previous year, driven by the expanding desensitization treatment market [2] Group 3: Product Usage and Costs - The treatment cost for "Dust mite drops" over a 2-year period is approximately 5,000 to 6,000 yuan [2] - The typical duration for patients using "Dust mite drops" is 2-3 years, with individual variations [2] Group 4: Market and Patient Demographics - The company’s products are primarily used in pediatrics, otolaryngology, respiratory, dermatology, and allergy departments [2] - The ratio of adult to child patients using sublingual desensitization drugs is currently indeterminate, but children generally show higher compliance [3] Group 5: Future Product Plans - "Artemisia annua powder drops" are planned for two indications: rhinitis and asthma, with adult trials preceding pediatric trials as per regulatory requirements [3] - The company is preparing for clinical trials for 9 ongoing products, with timelines for approval yet to be determined [3] Group 6: Investment and Strategic Development - The company has established Shanghai WoWu Stem Cell Technology Co., Ltd. with a registered capital of 150 million yuan and Zhejiang WoWu Stem Cell Technology Co., Ltd. with 30 million yuan, focusing on potential markets in elderly disease treatment and cell therapy [4]